纳武利尤单抗联合伊匹木单抗对比舒尼替尼一线治疗晚期肾细胞癌:III期CheckMate 214试验疗效与安全性的8年扩展随访结果
CheckMate 214研究8年随访显示,中/低危晚期肾细胞癌患者一线纳武利尤单抗联合伊匹木单抗对比舒尼替尼,总生存HR为0.69(95%CI 0.59-0.81),90个月无进展生存概率25.4% vs 8.5%,客观缓解率42.4% vs 27.5%,完全缓解率11.8% vs 2.6%。
要点
- 中/低危患者总生存HR 0.69(95%CI 0.59-0.81),纳武利尤单抗联合伊匹木单抗优于舒尼替尼。
- 90个月无进展生存概率中/低危25.4% vs 8.5%,意向治疗人群22.8% vs 10.8%。
- 中/低危客观缓解率42.4% vs 27.5%,完全缓解率11.8% vs 2.6%。
核心结论
- 8年随访时,纳武利尤单抗联合伊匹木单抗对比舒尼替尼在晚期肾细胞癌中维持了优效的生存获益、持久缓解获益和可控的安全性,为晚期肾细胞癌一线检查点抑制剂联合治疗中III期随访时间最长。
研究设计与样本
- III期CheckMate 214试验纳入晚期肾细胞癌患者1096例,随机分配至纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg每3周一次共4次后纳武利尤单抗(3 mg/kg或240 mg每2周一次或480 mg每4周一次),或舒尼替尼50 mg每日一次服4周停2周。
- 主要终点为中/低危患者的独立影像学评审委员会评估的无进展生存和总生存;意向治疗人群为次要终点;有利风险人群为探索性分析。
主要发现
- 中位随访99.1个月(8年)时,总生存HR:意向治疗人群0.72(95%CI 0.62-0.83),中/低危人群0.69(95%CI 0.59-0.81),有利风险人群0.82(95%CI 0.60-1.13)。
- 90个月无进展生存概率:纳武利尤单抗联合伊匹木单抗 vs 舒尼替尼在意向治疗人群为22.8% vs 10.8%,中/低危人群25.4% vs 8.5%,有利风险人群12.7% vs 17.0%。
- 客观缓解率:意向治疗人群39.5% vs 33.0%,中/低危人群42.4% vs 27.5%,有利风险人群29.6% vs 51.6%。
- 完全缓解率:意向治疗人群12.0% vs 3.5%,中/低危人群11.8% vs 2.6%,有利风险人群12.8% vs 6.5%。
- 中位缓解持续时间:意向治疗人群76.2个月(95%CI 59.1个月-不可估计)vs 25.1个月(95%CI 19.8-33.2个月),中/低危人群82.8个月(95%CI 54.1个月-不可估计)vs 19.8个月(95%CI 16.4-26.4个月),有利风险人群61.5个月(95%CI 27.8个月-不可估计)vs 33.2个月(95%CI 24.8-51.4个月)。
关键数值与推荐
- 中/低危患者总生存HR 0.69(95%CI 0.59-0.81),意向治疗人群HR 0.72(95%CI 0.62-0.83),有利风险人群HR 0.82(95%CI 0.60-1.13)。
- 90个月无进展生存概率中/低危25.4% vs 8.5%。
- 客观缓解率中/低危42.4% vs 27.5%。
- 完全缓解率中/低危11.8% vs 2.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 有利风险人群的探索性事后分析需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab plus ipilimumab (NIVO+IPI) has demonstrated superior overall survival (OS) and durable response benefits versus sunitinib (SUN) with long-term follow-up in patients with advanced renal cell carcinoma (aRCC). We report updated analyses with 8 years of median follow-up from CheckMate 214. PATIENTS AND METHODS: Patients with aRCC (N = 1096) were randomized to NIVO 3 mg/kg plus IPI 1 mg/kg Q3W × four doses, followed by NIVO (3 mg/kg or 240 mg Q2W or 480 mg Q4W); or SUN (50 mg) once daily for 4 weeks on, 2 weeks off. The endpoints included OS, independent radiology review committee (IRRC)-assessed progression-free survival (PFS), and IRRC-assessed objective response rate (ORR) in intermediate/poor-risk (I/P; primary), intent-to-treat (ITT; secondary), and favorable-risk (FAV; exploratory) patients. RESULTS: With 8 years (99.1 months) of median follow-up, the hazard ratio [HR; 95% confidence interval (CI)] for OS with NIVO+IPI versus SUN was 0.72 (0.62-0.83) in ITT patients, 0.69 (0.59-0.81) in I/P patients, and 0.82 (0.60-1.13) in FAV patients. PFS probabilities at 90 months were 22.8% versus 10.8% (ITT), 25.4% versus 8.5% (I/P), and 12.7% versus 17.0% (FAV), respectively. ORR with NIVO+IPI versus SUN was 39.5% versus 33.0% (ITT), 42.4% versus 27.5% (I/P), and 29.6% versus 51.6% (FAV). Rates of complete response were higher with NIVO+IPI versus SUN in all International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups (ITT, 12.0% versus 3.5%; I/P, 11.8% versus 2.6%; FAV, 12.8% versus 6.5%). The median duration of response (95% CI) with NIVO+IPI versus SUN was 76.2 versus 25.1 months [59.1 months-not estimable (NE) versus 19.8-33.2 months] in ITT patients, 82.8 versus 19.8 months (54.1 months-NE versus 16.4-26.4 months) in I/P patients, and 61.5 versus 33.2 months (27.8 months-NE versus 24.8-51.4 months) in FAV patients. The incidence of treatment-related adverse events was consistent with previous reports. Exploratory post hoc analyses are reported for FAV patients, those receiving subsequent therapy based on their response status, clinical subpopulations, and adverse events over time. CONCLUSIONS: Superior survival, durable response benefits, and a manageable safety profile were maintained with NIVO+IPI versus SUN at 8 years, the longest phase III follow-up for a first-line checkpoint inhibitor combination therapy in aRCC.
引用
- Tannir NM, Albigès L, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2024. PMID: 39098455. doi:10.1016/j.annonc.2024.07.727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。